Zacks Research Has Positive Outlook for Novavax Q2 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Investment analysts at Zacks Research increased their Q2 2026 EPS estimates for shares of Novavax in a report issued on Friday, May 22nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn ($0.28) per share for the quarter, up from their previous forecast of ($0.29). The consensus estimate for Novavax’s current full-year earnings is ($0.20) per share. Zacks Research also issued estimates for Novavax’s Q4 2026 earnings at $0.29 EPS, FY2026 earnings at $0.03 EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at $0.08 EPS, FY2027 earnings at $0.01 EPS, Q1 2028 earnings at $0.06 EPS and FY2028 earnings at $1.29 EPS.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.19. The business had revenue of $118.90 million for the quarter, compared to analyst estimates of $79.81 million. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The company’s revenue was down 79.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.93 EPS.

Several other research analysts have also commented on NVAX. B. Riley Financial restated a “buy” rating on shares of Novavax in a report on Thursday, April 9th. Jefferies Financial Group reissued a “buy” rating on shares of Novavax in a research note on Thursday, March 12th. HC Wainwright lifted their target price on shares of Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, February 27th. Wall Street Zen downgraded Novavax from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings lowered Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $12.13.

Novavax Price Performance

Shares of NVAX stock opened at $10.46 on Wednesday. The firm has a market cap of $1.72 billion, a P/E ratio of -18.03 and a beta of 2.37. Novavax has a 1-year low of $6.13 and a 1-year high of $11.97. The firm’s 50-day simple moving average is $8.83 and its 200-day simple moving average is $8.30.

Institutional Trading of Novavax

Hedge funds and other institutional investors have recently modified their holdings of the business. Shah Capital Management increased its holdings in Novavax by 23.3% during the 4th quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock worth $97,835,000 after purchasing an additional 2,747,000 shares during the last quarter. State Street Corp grew its position in shares of Novavax by 32.3% during the fourth quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock worth $63,999,000 after buying an additional 2,326,927 shares in the last quarter. UBS Group AG increased its stake in shares of Novavax by 40.3% in the fourth quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock worth $32,890,000 after buying an additional 1,405,981 shares during the last quarter. Allianz Asset Management GmbH raised its holdings in Novavax by 162.6% in the third quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock valued at $12,222,000 after acquiring an additional 872,987 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its stake in Novavax by 4,775.0% during the 3rd quarter. Farallon Capital Management LLC now owns 780,000 shares of the biopharmaceutical company’s stock valued at $6,763,000 after acquiring an additional 764,000 shares during the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.